These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 27270045)

  • 21. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population.
    Liem YS; Wong JB; Winkelmayer WC; Weimar W; Wetzels JF; de Charro FT; Kaandorp GC; Stijnen T; Hunink MG
    Nephrol Dial Transplant; 2012 Jan; 27(1):429-34. PubMed ID: 21606383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.
    Narayan R; Perkins RM; Berbano EP; Yuan CM; Neff RT; Sawyers ES; Yeo FE; Vidal-Trecan GM; Abbott KC
    Am J Kidney Dis; 2007 Jun; 49(6):801-13. PubMed ID: 17533023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
    JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.
    Chang RW; Pellisier JM; Hazen GB
    JAMA; 1996 Mar; 275(11):858-65. PubMed ID: 8596224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Societal value of stem cell therapy in stroke--a modeling study.
    Svensson J; Ghatnekar O; Lindgren A; Lindvall O; Norrving B; Persson U; Kokaia Z
    Cerebrovasc Dis; 2012; 33(6):532-9. PubMed ID: 22571941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation.
    Simon DG
    Med Decis Making; 1986; 6(4):199-207. PubMed ID: 3095605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health economic evaluations: the special case of end-stage renal disease treatment.
    Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
    Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.